<DOC>
	<DOCNO>NCT00274612</DOCNO>
	<brief_summary>The primary objective study demonstrate telmisartan 80 mg ( MICARDIS® ) least effective possibly superior ramipril 5mg 10mg lower mean ambulatory diastolic blood pressure ( DBP ) systolic blood pressure ( SBP ) last 6 hour 24-hour dose interval mild-to-moderate hypertensive patient end 8 14-week treatment period , respectively .</brief_summary>
	<brief_title>Prospective Randomised Investigation Safety Efficacy Micardis® v Ramipril Using ABPM</brief_title>
	<detailed_description>Secondary objective compare telmisartan ( 80 mg ) ( MICARDIS® ramipril ( 5 mg 10 mg ) : 1 ) reduction last 6-hour ABPM mean pulse pressure ( PP ) relative dosing , 2 ) reduction 24-hour ABPM mean DBP , SBP PP relative dosing , 3 ) reduction ABPM mean DBP , SBP PP period 24-hour dose interval ( i.e. , morning , daytime , nighttime ) relative clock time , 4 ) change baseline systolic diastolic blood pressure load 24-hour dosing interval , 5 ) reduction mean seat trough DBP SBP measure use manual in-clinic cuff sphygmomanometer , 6 ) responder rate determine ABPM manual in-clinic cuff measurement 7 ) Health-Related Quality Life ( HRQL ) . Study Hypothesis : It hypothesise rise blood pressure ( BP ) last hour sleep period cause high incidence cardiovascular event morning . The purpose present study demonstrate telmisartan ( MICARDIS® ) inferior ramipril lower blood pressure patient mild-to-moderate hypertension . Blood pressure assess ambulatory blood pressure monitoring ( ABPM ) allow comparison full 24-hour effect treatment without artefact ( e.g. , white-coat hypertension ) introduce measurement blood pressure clinic . This measure diastolic blood pressure entire 24-hour dosing interval , primary attention focus last six hour dose interval . NULL AND ALTERNATIVE HYPOTHESES In order test multiple hypothesis ( e.g. , non-inferiority superiority telmisartan compare ramipril ) , multiple dosage ( i.e. , telmisartan 80mg ( MICARDIS® ) versus ramipril 5mg ramipril 10mg 8 14 week treatment , respectively ) , two endpoint ( i.e. , reduction DBP SBP last 6 hour 24-hour dose interval ) measure ABPM , completely hierarchical , close test procedure use . Hierarchical Closed Testing Procedure : 1 . Non-inferiority telmisartan 80 mg ( MICARDIS® ) compare ramipril 5 mg end 8 week treatment period reduction DBP last 6 hour 24 hour dose interval ; significant , 2 . Superiority telmisartan 80 mg ( MICARDIS® ) compare ramipril 5 mg end 8-week treatment period reduction DBP last 6 hour 24-hour dose interval ; significant , 3 . Superiority telmisartan 80mg ( MICARDIS® ) compare ramipril 5 mg end 8-week treatment period reduction SBP last 6 hour 24-hour dose interval ; significant , 4 . Non-inferiority telmisartan 80mg ( MICARDIS® ) compare ramipril 10 mg end 14 week treatment period reduction DBP last 6 hour 24-hour dose interval ; significant , 5 . Superiority telmisartan 80mg ( MICARDIS® ) compare ramipril 10 mg end 14-week treatment period reduction DBP last 6 hour 24-hour dose interval ; significant , 6 . Superiority telmisartan 80mg ( MICARDIS® ) compare ramipril 10mg end 14-week treatment period reduction SBP last 6 hour 24-hour dose interval . A difference 2 mmHg determine maximum difference mean reduction DBP last 6 hour 24-hour dose interval two treatment would consider clinical importance ( i.e. , limit non inferiority ) . Thus non-inferiority telmisartan compare ramipril test use follow set hypothesis : Null Hypothesis : The overall mean reduction baseline ABPM mean DBP last 6 hour 24-hour dose interval telmisartan 80 mg ( MICARDIS® ) inferior ramipril least 2 mmHg . Alternative Hypothesis : The overall mean reduction baseline ABPM mean DBP last 6 hour 24-hour dose interval telmisartan 80mg ( MICARDIS® ) less 2 mmHg small ramipril . These hypothesis state : H0 : dT - dR le equal -2 mmHg versus HA : dT - dR &gt; -2 mmHg dT dR represent overall mean reduction baseline ABPM mean DBP last 6 hour 24-hour dose interval telmisartan ramipril , respectively , adjust factor include statistical model . If low limit two-sided 95 % confidence interval difference least square mean treatment ( telmisartan - ramipril ) lie -2 mmHg , conclude telmisartan 80mg ( MICARDIS® ) least effective ramipril ( 5mg 8 week treatment 10mg 14 week treatment , depend upon comparison ) reduce DBP last 6 hour 24-hour dose interval . Superiority telmisartan ( MICARDIS® ) compare ramipril test use follow set hypothesis : Null Hypothesis : The overall mean reduction baseline ABPM mean last 6 hour 24-hour dose interval telmisartan 80mg ( MICARDIS® ) less equal ramipril . Alternative Hypothesis : The overall mean reduction baseline ABPM mean last 6 hour 24-hour dose interval telmisartan 80mg ( MICARDIS® ) great ramipril . These hypothesis state : H0 : dT - dR le equal 0 mmHg versus HA : dT - dR &gt; 0 mmHg dT dR represent overall mean reduction baseline ABPM mean DBP last 6 hour 24-hour dose interval telmisartan ramipril , respectively , adjust factor include statistical model . If low limit two-sided 95 % confidence interval difference least square mean treatment ( telmisartan ( MICARDIS® ) - ramipril ) great zero , conclude telmisartan 80mg ( MICARDIS® ) statistically superior ramipril ( 5mg 8 week treatment 10mg 14 week treatment , depend upon comparison ) reduce blood pressure ( DBP SBP , depend upon comparison ) last 6 hour 24-hour dose interval . Comparison ( ) : Reductions blood pressure last 6 hour 24-hour dose interval measure ABPM patient treat telmisartan ( MICARDIS® ) compare patient treat ramipril . The primary analysis consist close test procedure first test non-inferiority telmisartan 80mg ( MICARDIS® ) compare ramipril 10mg fourteen week treatment reduction diastolic blood pressure ( DBP ) ; significant , test superiority telmisartan 80 mg ( MICARDIS® ) compare ramipril 10 mg reduction DBP ; significant , test superiority telmisartan 80 mg ( MICARDIS® ) compare ramipril 10 mg reduction systolic blood pressure ( SBP ) ; significant , test non-inferiority telmisartan 80 mg ( MICARDIS® ) compare ramipril 5 mg eight week treatment reduction DBP ; significant , test superiority telmisartan 80 mg ( MICARDIS® ) compare ramipril 5 mg reduction DBP ; significant , test superiority telmisartan 80mg ( MICARDIS® ) compare ramipril 5mg reduction SBP .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>1 . Mildtomoderate hypertension define mean seat diastolic blood pressure great equal 95 mmHg less equal 109 mmHg , measure manual cuff sphygmomanometer Visit 2 . 2 . 24hour mean DBP great equal 85 mmHg Visit 3 measure ABPM . 3 . Age 18 year old . 4 . Ability stop current antihypertensive therapy without risk patient ( investigator 's discretion ) . 5 . Ability provide write informed consent accordance GCP local legislation . 1 . Premenopausal woman ( last menstruation approximately less equal 1 year prior sign informed consent ) : Are surgically sterile Are nursing , Are childbearing potential NOT practice acceptable method birth control , NOT plan continue practice acceptable method throughout study . Acceptable method birth control include intra uterine device , oral , implantable injectable contraceptive . 2 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 A.M. 3 . Mean sit SBP great equal to180 mmHg mean sit DBP great equal 110 mmHg visit placebo runin period . 4 . Known suspected secondary hypertension ( i.e. , pheochromocytoma ) . 5 . Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) SGOT ( AST ) &gt; 2 time upper limit normal range . Serum creatinine &gt; 2.3mg/dL ( &gt; 203 micromol/l ) . 6 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant patient patient one kidney . 7 . Clinically relevant sodium depletion , hypokalaemia hyperkalaemia . 8 . Uncorrected volume depletion . 9 . Primary aldosteronism . 10 . Hereditary fructose intolerance . 11 . Biliary obstructive disorder . 12 . Congestive heart failure ( NYHA functional class CHF IIIIV ) . 13 . Unstable angina within past three month prior start run period . 14 . Stroke within past six month prior start run period . 15 . Myocardial infarction cardiac surgery within past three month prior start run period . 16 . PTCA ( percutaneous transluminal coronary angioplasty ) within past three month prior start run period . 17 . Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator . 18 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , haemodynamically relevant stenosis aortic mitral valve . 19 . Patients insulindependent diabetes mellitus whose diabetes stable control least past three month define HbA1C great equal 10 % . 20 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist . 21 . History drug alcohol dependency within 6 month prior start run period . 22 . Concomitant administration medication know affect blood pressure , except medication allow protocol . 23 . Any investigational therapy within one month start run period . 24 . Known hypersensitivity component formulation . 25 . Any clinical condition , opinion investigator would allow safe completion protocol safe administration trial medication . 26 . Inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>